{"schema_version":"secwatch.filing_event.v1","accession":"0001397702-24-000029","form_type":"8-K","ticker":null,"cik":"0001397702","company_name":"Silk Road Medical Inc","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.234890+00:00","generated_at":"2026-06-03T04:14:59.573041+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Silk Road Medical Q1 2024 revenue $48.5M (+21% YoY); net loss narrows to $14.1M","bullets":["Revenue $48.5M, up 21% YoY driven by increased TCAR adoption.","Gross margin 75%, up from 69% YoY due to favorable production variances.","Net loss $14.1M ($0.36/share) vs $16.5M ($0.43/share) in Q1 2023.","Adjusted EBITDA loss improved to $3.9M from $7.4M in Q1 2023.","CEO cites commercial progress and steps toward sustainable profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0001397702-24-000029","json":"https://secwatch.observer/filing/0001397702-24-000029.json","markdown":"https://secwatch.observer/filing/0001397702-24-000029.md","text":"https://secwatch.observer/filing/0001397702-24-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1397702/000139770224000029/0001397702-24-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1397702/000139770224000029/silk-20240430x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:14:59.573041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d19ae5d92f13f8ad24aaea44213717b6ab387cf","claim":"Silk Road Medical Inc reported the three months ended March 31, 2024 results: revenue $48.5 million, EPS $0.36 per share.","evidence_excerpt":"and patients and in our opportunity to drive strong, sustainable growth as a business.”  First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $48.5 million, an increase of $8.4 million or 21%, compared to the first quarter of 2023. Growth was driven primarily by increased TCAR adoption.  Gross profit for the first quarter of 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1397702/000139770224000029/0001397702-24-000029-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$48.5 million"},{"label":"EPS","value":"$0.36 per share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}